Maina joined Sofinnova Partners as a partner in 2018, bringing an extensive network and a long track record as a successful healthcare investor. Prior to joining Sofinnova Partners, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London, where she led and co-led investments in the U.K. Before turning to investing, Maina worked in the R&D teams of several U.K. and U.S. biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine. Maina holds a B.S. from the University of Texas at Austin and an MBA from the Imperial Business School. Her current investments include Sitryx Therapeutics, Cincor and Enyo Pharma.